Rapid drug development, smooth conduct of clinical trials and fast time-to-market are high priorities for pharmaceuticals players. For drugs designed for subcutaneous application, self-injection pens from Haselmeier can help reduce risk and shorten time-to-market.
Support for clinical trials
Haselmeier's D-Flex ecosystem supports the entire development and commercial life of a drug with one single platform.
D-Flex can be configured to meet dose values from the first clinical study to series production, reducing time-to-market.
D-Flex helps lower cost in clinical trials, for example by supporting simultaneous device development.
A complete solution offering for pharmaceutical companies and biotech start-ups
To be deemed suitable for use in clinical trials, injection pens must be safe and simple to use, as well as supporting flexibility in the adjustment of the dose in phases 2 and 3. In addition, these devices must support continuous use with minimum adjustments for all phases of the clinical study up to drug approval. Haselmeier's D-Flex product platform can be configured for several fixed doses and values can be freely selected, making the device especially useful in dose-escalation studies, for example. The pen system does not allow any intermediate steps between the set doses, significantly reducing the risk of an incorrect dose and therefore supporting patient safety. Moreover, the D-Flex product platform pen can be quickly and cost-efficiently adjusted to meet customer requirements in terms of clinical-trial design, by replacing just one single part of the device. Modifications after phase 2 are possible and the drug delivery device can be adjusted to the requirements of other products in the drug development pipeline.
Supporting you at every step – from clinical trial to commercial product
Let's discuss how Haselmeier's solutions can help you overcome your clinical trial challenges.